UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~May 176, 2025

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37852		98-0505495
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

(510) 474-0170

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001		PTGX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 82.0102. ~~Other~~Results ~~Information~~of Operations and Financial Condition.

On ~~March~~May 176, 2025, Protagonist Therapeutics, Inc. ~~(the “Company”)~~ ~~and~~reported ~~Takeda~~its ~~Pharmaceuticals~~financial ~~USA, Inc.~~results ~~(“Takeda”)~~for ~~agreed, pursuant to~~ the ~~provisions~~first ofquarter ~~the~~ended ~~parties’ License and Collaboration Agreement dated January~~March 31, ~~2024,~~2025. asA ~~amended,~~copy ~~that Takeda will assume responsibility for leading and implementing the regulatory strategy and associated activities for preparation~~ of the ~~New~~press ~~Drug~~release ~~Application~~titled ~~related to rusfertide in polycythemia vera to~~“Protagonist beReports ~~submitted~~First ~~with~~Quarter ~~the~~2025 ~~United~~Financial ~~States~~Results ~~Food~~ and ~~Drug~~Provides ~~Administration.~~Corporate ~~The~~Update” ~~transition~~is tofurnished ~~Takeda~~pursuant ofto ~~leadership~~Item ~~for~~2.02 ~~NDA~~as ~~preparation is underway~~Exhibit 99.1 ~~The~~hereto ~~Company~~and ~~remains~~is ~~primarily~~incorporated ~~responsible~~herein ~~for~~by ~~clinical development activities through NDA filing~~reference.

~~SIGNATURE~~Item 9.01 Financial Statements and Exhibits.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~(d) Exhibits

Dated: March 20, 2025

Exhibit No.		Description
99.1		Press release, dated May 6, 2025, titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update.”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., ~~By:~~whether ~~/s/~~made ~~Asif~~before ~~Ali~~or ~~Asif~~after ~~Ali~~the ~~Chief~~date ~~Financial~~hereof, ~~Officer~~regardless of any general incorporation language in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Protagonist Therapeutics, Inc.
Dated: May 6, 2025
	By:	/s/ Asif Ali
		Asif Ali
		Chief Financial Officer

Filing Compare · Protagonist Therapeutics, Inc